















IPO Porto,

Rua Dr. António Bernardino de Almeida 4200-072 Porto, Portugal

3-6 April 2024

EXECUTIVE SUMMARY

The PCM4EU Academy is a 4-day session aimed at implementing the science of precision medicine in oncology across Europe. The academy invites you as an investigator and PCM4EU partner. Join us for an intensive week to develop clinical trial protocols, implement new tools within MTBs and build a multi-stakeholder organisation around DRUP trials. We will implement interactive educational workshops to promote your work around these topics. You will attend high-quality guest lectures, work in small groups around specialised topics, benefit from educational tools to address your topics, and participate in experience sharing sessions. Take the opportunity to interact with experienced researchers and guest speakers from different institutions and countries with expertise in all areas of clinical research and precision medicine and expand your network.

This initiative is supported by the personalised cancer medicine project for all EU citizens (PCM4EU), funded by EU4Health, Europe Fighting Cancer, grant 101079984.

Target audience:

The ideal trainee is a young oncologist, pathologist, biologist

(with a background in oncology and/or molecular diagnostics with interest in clinical trials such as DLCTs and international collaboration).

Table of contents

Speakers	3
Spring academy program	5
Organizing committee	9
Practical information	10

Speakers



Hans Gelderblom MD, PhD, Professor and Medical Oncologist, Leiden University Medical Centre, The Netherlands



Jean-Yves Blay MD, PhD, Centre Leon Berard, France



Iwona Lugowska
MD, PhD,
Maria Sklodowska-Curie
National Research Institute
Poland



Loic Verlingue MD, PhD, Centre Leon Berard, France



Anders Edsjo MD, PhD, Region Skane, Sweden



Júlio Oliveira
President of IPO Porto
Instituto Português de Oncologia
do Porto (IPO Porto), Portugal



Ana Peixoto
PharmD, PhD,
Clinical Biologist - Genetics
Instituto Português de Oncologia
do Porto (IPO Porto), Portugal



Kjetil Taskén MD, PhD, Head of Institute for Cancer Research, Oslo University Hospital, Norway



Bettina Ryll MD, PhD, Stockholm School of Economics Institute for ResearchS and founder of Melanoma Patient Network Europe



Ebba Hallersjö Hult Co-Founder & Head of Vision Zero Cancer, Stockholm school of Economics, Sweden



Ulrik Lassen
Professor, MD, PhD,
Department of Oncology
Rigshospitalet, Copenhagen
Denmark



Rui Henrique MD, PhD, Head of Pathology Instituto Português de Oncologia do Porto (IPO Porto), Portugal



Hege Russnes
Professor, MD, PhD,
Oslo University Hospital,
Norway



Edita Baltruskeviciene
MD, Head of Clinical Trials Group
National Cancer Institute,
Lithuana

Speakers



Kristiina Ojamaa Head of Hematology-Oncology Clinic Tartu University Hospital, Estonia



Rui Santos Ivo
President of INFARMED & Chair of the Heads of HTA Agencies group, I.P.,
National Authority of Medicines and Healthcare Products
Portugal



Maeve Lowery
Professor, Medical Oncologist
St James's Hospital
Ireland



Lucy Morgan
Director of Research and Policy,
The Health Policy Partnership
United Kingdom



Eliel Katche Medical data scientist, Centre Leon Berard, France



Suzanne Wait PhD, Co-founder & Managing Director, The Health Policy Partnership, United Kingdom



Paola Zagami European oncology institure, Italy



Hugo R. Soares PhD, Science Manager, Research and Innovation Networks, AICIB, Coordinator ECHoS project Portugal



Soemeya Haj Mohammad MD, PhD student Leiden University Medical Center, The Netherlands



Anni Lepland
PhD, Senior specialist,
Tartu University Hospital
Estonia



Irene Braña MD, PhD, Head of VHIO, Spain



Henriett Butz
MD, PhD
National institute of Oncology,
Hungray

PCM4EU Spring Academy, day #1 - 3rd April 2024 PAST, PRESENT & FUTURE of Personalized Cancer Medicine in Europe

Room: Auditório Principal Chair:

Hans Gelderblom, Kjetil Tasken, Bettina Ryll, Iwona Lugowska, Loic Verlingue

13:15 - 13:25 Welcome - Hans Gerderblom & Julio Oliveira

13:25 - 13:45 Warming up PCM quiz - Iwona Lugowska

SESSION 1: THE PAST

Learning from the past ten years of precision medicine in oncology

Moderator : Iwona Lugowska

13:45 - 14:25 • Timeline of Drup-like trials - Hans Gerderblom (20 minutes)

• PM innovations in the last 10 years - Jean-Yves Blay (20 minutes)

14:25 - 14:45 Q&A round table: «What can we learn from the past?»

Jean-Yves Blay, Hans Gelderblom, Julio Oliveira & Edita Baltruskeviciene

SESSION 2: THE PRESENT

Getting DLCTs to every patient in Europe.

Moderator : Kjetil Tasken

Setting Districts over/ patient in Esteps

• Widening application - Kristiina Ojamaa (15 minutes)

• Western E.U perspective & cross border access to trials

Maeve Lowery (15 minutes)

Patient engagement in research: «better research

& a competitive advantage in grant applications» - Bettina Ryll (15 minutes)

• Access to genomic data: «Handle & federate genomic datas»

Attila Patocs (15 minutes)

15:45 - 16:05 Q&A and discussion

16:05 - 16:50 COFFEE BREAK

SESSION 3 : THE FUTURE - Precision medicine, a new type of medicine: finding your place in a system dependent on successful multi-stakeholder collaboration

Moderator : Bettina Ryll

16:50 - 17:50

14:45 - 15:45

• Building successful multi-stakeholder collaborations in precision medicine - *Kjetil Tasken (15 minutes)*

• Precision medicine: challenges for regulatory & HTA decision-making - Rui Santos Ivo (15 minutes)

• Combine clinical care with an exciting research program Loic Verlingue (15 minutes)

• Become an interesting collaborator for pharma and biotech Iwona Lugowska (15 minutes)

17:50 - 18:10 Q&A and discussion

18:10 - 18:30 The second edition of PCM quiz - Iwona Lugowska

18:30 - 18:50 Conclusion - Hans Gelderblom

18:50 - 19:10 Presentation of spring academy objectives, program, output

Loic Verlingue, Iwona Lugowska

PCM4EU School, day #2 - 4th April 2024

Successfully implementing DLCTs:

navigating multi-stakeholder ecosystems and utilizing health system readiness frameworks

Room: EPOP Sala Multiuso Chair & Moderators:

Ebba Hallersjö Hult, Bettina Ryll

08:45 - 10:15

Introduction to DLCT ecosystems as complex adaptive systems:

what are penta-helix ecosystems, who is a part of it, why do they matter and how does one change them? Bettina Ryll

Study case-mapping DLCT ecosystems in widening countries (work conducted for the HORACE application)

Anni Lepland

10:15 - 10:45

COFFEE BREAK

10:45 - 12:15

Introduction to mission-driven innovation:

Vision Zero Cancer, a mission-driven innovation ecosystem in cancer: missions as a way to change complex systems, the importance of convenors and enablers, the art of balancing competing interests and agendas.

Ebba Hallersjö Hult

PCM4EU is ambassador to ECHoS

ECHoS- establishing national cancer mission hubs: Europe's cancer mission & Beating Cancer plan, opportunities for collaboration and synergies Hugo Soares, ECHoS coordinator

12:15 - 13:30

LUNCH BREAK

13:30 - 14:30

What is needed to implement a given innovation and how ready is your health system to implement this innovation?

An introduction to health system readiness frameworks and how to use them, Sweden as a study case and practical workshop where the 'innovation' being considered in this framework is PCM clinical trials, with a specific focus on diagnostics.

Ebba Hallersjö Hult, Suzanne Wait, Lucy Morgan, The Health Policy Partnership

14:30 - 15:00

COFFEE BREAK

15:00 - 17:00 P

Practical workshop

15:00 - 18:00

Overall conclusion of the day

LEARNING OBJECTIVES:



- Methods and tools to describe and analyse these ecosystems to inform action
- Mission-driven innovation as an approach to change complex adaptive systems, ongoing European initiatives in that space and opportunities for collaboration
- Readiness frameworks to assess a system's capacity to implement an innovation,
 to help identify barriers to effective implementation, to monitor progress and as advocacy tool
 to drive change.

PCM4EU School, day #3 - 5th April 2024

How to integrate technical tools for clinical decision support system in precision medicine

Room: EPOP Sala Muli	Chair & Moderators: Loic Verlingue, Manon Antouly
08:45 - 09:15	Overview of PCM4EU WP2 progress:
	tools for molecular testing and molecular tumour boards
	Hege Russnes & Anders Edsjo
09:15 - 10:15	Shared experience of CDSS tools in MTBs (Round table)
	Multi-presentation of available tools:
	Eliel Katche, Soemeya Haj Mohammad , Paola Zagami
	Iwona Lugowska, Rui Henrique, Henriett Butz

10:15 -	- 10:30	Conclusion

10:30 - 11:15	CC)FF	EE	BR	EAK
---------------	----	-----	----	----	-----

11:15 - 12:15 Workshop:

How to implement a new CDSS in your MTB

We will use ISHIKAWA root cause analysis, group discussion,

shared experience, ask the expert

1 topic per group:

- Trials Matching tools
- Functional interpretation of genomic alterations
- Legal authorisations for the medical use of these tools
- Image analysis (anapath, multiIF, scans...)
- New molecular analysis implementations

(Single cell RNAseq, multiIF, spatial transcriptomic analysis...)

12:15 - 13:30	LUNCH BREAK
13:30 - 14:30	Meet the expert
14:30 - 16:30	Action plans to implement your CDSS for your MTB
16:30 - 17:30	Oral presentation of each topic - Plenary session
17:30 - 17:50	Conclusion and perspectives
20:00	3 hours boat cruise with dinner

LEARNING OBJECTIVES:

How to integrate technical tools for clinical decision support in precision medicine

- Gaining knowledge about existing CDSS and their use.
- Knowing how to implement and design new CDSS applications and evaluate them.
- Sharing experience on the current organization of Molecular Tumor Boards in the PCM4EU consortium

PCM4EU School, day #4 - 6th April 2024

Clinical trial and design drug trial protocols

Room:

EPOP Sala Multiuso

Chair & Moderators: Iwona Lugowska, Ulrik Lassen

08:45 - 09:10	Introduction to the clinical trial & design drug trial protocols - Kjetil Tasken
09:10 - 09:45	New drugs development - Irene Braña
09:45 - 10:00	Conclusion of Spring Academy: take home messages, future plans and perspectives Hans Gelderblom, Iwona Lugowska, Loic Verlingue

DLCT Investigators meeting

All trainees interested are welcome to join, especially interest in protarget study

10:00 - 11:45 IMPLEMENTATION OF DLCT STEP BY STEP

Study & protocol presentation - Kristoffer Rohrberg, Tina Kringelbach

- · Protocol presentation
- Study procedure including molecular testing and molecular tumor board
- Investigational products management
- Translational research inclusion, laboratory manual
- Financing
- Trial Master File and introduction to data management tools (eCRF)

11:45 - 12:00 COFFEE BREAK

12:00 - 13:45 IMPLEMENTATION OF DLCT STEP BY STEP

Tips for study start-up, study execution & closeout

Kristoffer Rohrberg, Tina Kringelbach

- Study Feasibility
- Study submission and EU Clinical Trials Regulation (including IVDR)
- Contract and budget development (legal, GDPR, insurance)

13:45 - 14:00 Closing remarks on DLCT step by step

Hans Gelderblom, Kjetil Tasken, Iwona Lugowska

14:00 Lunch & Network, opportunnity of lunch bag

LEARNING OBJECTIVES:

Clinical trial and design drug trial protocols

- Understanding clinical trials dedicated to development of personalised medicnie
- Implementation of DRUP-like trials in Europe
- Network building based on the standarised approach and a high quality of clinical research



Organizing committee

For questions relating to content:



Loic Verlingue Work package 6 Co-Leader Centre Léon Bérard, France



Manon Antouly Work package 6 Co-Leader Centre Léon Bérard, France



Iwona Lugowska
Work package 6 Co-Leader
Maria Sklodowska-Curie National
Research Institute, Poland



Agnieszka Janowska Work package 6 Co-Leader Maria Sklodowska-Curie National Research Institute, Poland



Bettina Ryll
Work package 5 Co-Leader
Stockholm School of Economics
Institute. Sweden



Ebba Hallersjö Hult Work package 4 Co-Leader Stockholm School of Economics Institute, Sweden

Local hosts: IPO PORTO



Júlio Oliveira Local host,President of IPO Porto Instituto Português de Oncologia do Porto (IPO Porto), Portugal



For logistics and finance:

Hans Gelderblom Work package 1 Leader Leiden University Medical Centre, The Netherlands



Rui Henrique Local host, Instituto Português de Oncologia do Porto (IPO Porto), Portugal



Emmanuela Lonardi
Work package 1 Leader
Leiden University Medical Centre,
Project manager &
PCM4EU consortium coordinator
The Netherlands



Beatrice Mainoli
MD, Clinical Pharmacologist
Moderator, Logistics
Instituto Português de Oncologia
do Porto (IPO Porto), Portugal



Joana Monteiro
Local host, Communication
Instituto Português de Oncologia
do Porto (IPO Porto), Portugal

Practical information

Adress venue:

- Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto)
- Rua Dr. António Bernardino de Almeida 4200-072 Porto
- Phone number: +351 225 084 000

Transportation & Taxi:

- The most effective and also the most affordable way to reach Porto city center upon arrival at Porto Airport Francisco Sá Carneiro, is to take the metro. From the Airport, you can take the metro line E (Purple line) and get off at the Trindade stop to take the line D (Yellow line) to IPO.
- If you prefer to take a taxi directly from the airport, feel free to book via online booking platforms (Uber, Bolt, Freenow or Heetch) or book a taxi directly on arrival outside the airport.

Internet:

• Wifi: IPOP-Guest (open) - no password

Spring school dinner and social activities:

- Social dinner on Tuesday 2nd April
- 3 hours boat cruise with dinner on Friday 5th April

Hotel location:

· IBIS HOTEL:

Rua Dr. Placido Costa, Paranhos, 4200-450 Porto, Portugal

· Eurostar Hotel:

Eurostars Oporto, R. Mte. Guilherme Camarinha 212, 4200-537 Porto, Portugal

For more details, please check the information in the confirmation email